Lutonix 035 (Model 9004 and Model 9010)
Lutonix · Decision date Sep 4, 2025
What did the FDA decide?
FDA records P130024/S044 as a supplement to PMA P130024, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 4, 2025.
FDA approval order statement
reducing the frequency of residual solvent testing from every individual lot to a single lot per month
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 4, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130024/S044
- Regulatory pathway
- PMA supplement
- Applicant
- Lutonix
- Product code
- ONU
- Decision code
- OK30
- Decision date
- Sep 4, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130024/S044 received
Application receipt date recorded by FDA.
P130024/S044 · FDA decision
30-Day Notice
P130024/S045 · Related supplement
Lutonix 035 Drug Coated Balloon Catheter
Timeline entries are records held by MedtechLedger for P130024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lutonix 035 Drug Coated Balloon CatheterP130024/S045 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
Explore the linked device profile
Other records with product code ONU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
Ranger Paclitaxel-Coated Balloon CatheterP190019/S043 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 4, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 21, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lutonix
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9409 Science Center Dr., New Hope, MN, 55428
Sources and methodology
- Original FDA record: P130024/S044
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records